CLINICAL ROLE -
Alexandra S. Wolff, PharmD, BCOP, comments on her experience with CPX-351 in clinical practice and the potential to combine CPX-351 with targeted agents for AML.
Study Shows Older Patients With AML Respond to Treatment With VEN-HMA
Pharmacy Focus Oncology: Advancements in Hematology and Breast Cancer - ASH and SABCS 2023 Recap
FDA Approves Updated Label for Altuviiio to include Full Data on Pediatric Patients With Hemophilia A
Pharmacy Focus: Oncology Edition - Experts See Promising Future for the Treatment of Acute Lymphoblastic Leukemia
Commercializing CRISPR/Cas9 Therapy: FDA Approval of Exa-Cel Marks Milestone in Treatment Development
FDA Grants 510(k) Clearance for Rika Plasma Donation System